Prostate Cancer Coverage from Every Angle
Advertisement
Advertisement

Maha H.A. Hussain, MD, on Castration-Resistant Prostate Cancer: Future Directions for PARP Inhibitors

Posted: Monday, October 7, 2019

Maha H.A. Hussain, MD, of Northwestern University Robert H. Lurie Comprehensive Cancer Center, discusses the findings of the PROfound trial with olaparib in metastatic castration-resistant prostate cancer, and other PARP inhibitors that are likely to be studied in this setting.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.